Phase 2 Retinitis Pigmentosa Treatment Completed

 

R-Tech Ueno Ltd. (Tokyo, Japan) announced it has completed a phase 2 clinical trial of 0.15% UF-021 isopropyl unoprostone (Ocuseva), which is under development as a treatment for retinitis pigmentosa (RP). The trial investigated the possibility of improving visual function in the central part of the retina with UF-021 in patients with RP.

The randomized, multicenter, comparative study examined 112 patients with RP that had progressed to the mid-to late-stage, defined as a visual acuity of 0.5 or more with a narrow visual field. Patients received placebo or Ocuseva, instilled one drop per time or two drops per time (at a 5 minute interval), twice a day in the morning and evening for 24 weeks. The primary efficacy endpoint was the change in the mean retinal sensitivity of the central 2° of the ocular fundus measured with an MP-1 microperimeter (Nidek, Gamagori, Japan), according to a company news release. Retinal sensitivity by Humphrey perimeter (10-2), visual acuity, contrast sensitivity, and health-related quality of life, using a questionnaire on visual function (VFQ-25), were also evaluated.

After 24 weeks, positive change in the retinal sensitivity of the central 2° from baseline increased the most in the two-drops-per-time group, followed by the onedrop- per-time group. The placebo group had the least significant increase in sensitivity. The change in the retinal sensitivity from the pretreatment level by 4 dB or more was seen as improvement in 15.2% of patients in the placebo group, 7.9% in the one-drop-per-time group, and 18.4% in the two-drops-per-time group, whereas the change was seen as aggravation in 21.2% in the placebo group, 15.8% in the one-drop-per-time group, and 2.6% in the two-drops-per-time group. There were a significantly lower number of aggravated cases in the 2-drops-per-time group, compared with the placebo group, according to R-Tech Ueno. The retinal sensitivity measured with the Humphrey perimeter showed statistically significant improvement at weeks 4 and 8 in the two-drops-per-time group compared with the placebo group.

The main adverse effect of Ocuseva was ocular irritation, which, the company said, disappears several minutes after instillation.

 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman
Editor-in-Chief
484-581-1827
kroman@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.